SMALL MOLECULES {#s0010}
===============

Leflunomide and Malononitrilamides {#s0015}
----------------------------------

Leflunomide, initially developed as an agriculture herbicide, was explored as an immunosuppressant because of its ability to inhibit the enzyme dihydroorotate dehydrogenase.[@bb0075] The potential of leflunomide as an immunosuppressant in the field of transplantation was extensively demonstrated in various experimental studies, but its long half-life (several days) poses the problem of potential overimmunosuppression in transplant patients. Analogues of the active metabolite of leflunomide have been developed and are called malononitrilamides (MNAs). FK778 (also known as MNA715 or HMR1715) is the best studied synthetic MNA, and as it has a much shorter half-life than leflunomide (6--45 hours versus 15--18 days) it was believed to represent an attractive alternative to leflunomide for application in organ transplantation.[@bb0565]

### Chemical Structure and Pharmacology {#s0020}

Leflunomide (*N*-(4)) trifluoro-methylphenyl-5-methylisoxawol-4-carboximide) is a prodrug and is rapidly converted to its biologically active metabolite teriflunomide (A771703). Serum levels of teriflunomide are referred to as leflunomide levels. The half-life of teriflunomide is long in humans (approximately 15 days). The drug enters the enterohepatic recirculation and is excreted by the intestinal and urinary systems in equal proportions. Leflunomide is insoluble in water and is suspended in 1% carboxymethylcellulose for oral administration.

The MNAs are designed to be structurally similar to A771726. Oral bioavailability of FK778 is not substantially affected by food, and no gender effect on pharmacokinetics was observed in phase I studies.

### Mechanism of Action {#s0025}

Leflunomide and its analogues have strong antiproliferative effects on both T lymphocytes and B lymphocytes, thus limiting the formation of antibodies.[@bb0210] [@bb1145] Inhibition of pyrimidine synthesis is the most important mechanism of action as leflunomide directly inhibits the enzyme dihydroorotate dehydrogenase.[@bb1450] Lymphocytes rely entirely on the de novo pathway of pyrimidine biosynthesis and cannot use another, the so-called "pyrimidine salvage pathway." Dihydroorotate dehydrogenase inhibition leads to depletion of the nucleotide precursors uridine triphosphate and cytidine triphosphate which are necessary for the synthesis of RNA and DNA, and hence strongly suppress DNA and RNA synthesis.

The in vivo mechanism of action of leflunomide may depend on factors such as drug levels, disposable uridine pools, and the immune activation pathway involved. Studies have indicated that, in addition to inhibition of dihydroorotate dehydrogenase, leflunomide and the MNAs may act through inhibition of tyrosine kinases. Phosphorylation of the epidermal growth factor receptor of human fibroblasts has been shown to be inhibited by leflunomide.[@bb0805] It was shown that leflunomide directly inhibited the interleukin (IL)-2-stimulated protein tyrosine kinase activity of p56lck and p59fyn,[@bb0805] which is associated with activation through the T-cell receptor/CD3 complex. At higher concentrations, A771726 also inhibited IL-2-induced tyrosine phosphorylation of Janus kinase (JAK)1 and JAK3 protein tyrosine kinases.[@bb0305] Leflunomide analogues have also been shown to possess strong inhibitory activity on the antiapoptotic tyrosine kinase Bruton's tyrosine kinase, a key factor for T-cell-independent antibody formation.[@bb0755] The hypothesis that leflunomide may exhibit more than one mechanism of action in vivo was further illustrated in mice where uridine restored proliferation and IgM production by lipopolysaccharide-stimulated B cells, whereas suppression of IgG production was not reversed. This phenomenon correlated in a dose-dependent manner with tyrosine phosphorylation of JAK3 and STAT6 proteins, known to be involved in IL-4-induced signal transduction pathways.[@bb1145] This double in vivo mechanism of action was confirmed in rats, in which xenoreactivity was counteracted by the administration of uridine, whereas alloreactivity was not.[@bb0215]

Also inhibition of various macrophage functions by leflunomide and MNAs has been described; in particular, inhibition of the production of oxygen radicals,[@bb0080] [@bb0585] [@bb0785] the inhibition of IgE-mediated hypersensitivity responses,[@bb0555] the expression of IL-8 receptor type A, as well as tumor necrosis factor (TNF)-mediated nuclear factor kappa B (NF-κB) activation.[@bb0780] Tacrolimus also inhibits maturation of dendritic cells by preventing upregulation of activation markers and IL-12 production, and this phenomenon was not reversible by exogenous uridine. FK778 has equivalent or stronger immunosuppressive activity than leflunomide, both in vitro and in vivo.[@bb0565] The immunosuppressive effect is synergistic with that of calcineurin inhibitors (CNI) and mycophenolate mofetil (MMF).[@bb0110] [@bb0270]

Interestingly, FK778 and leflunomide have been shown to possess antiviral effects, although the precise mechanism is unclear: inhibition of viral replication of members of the herpesvirus family by preventing tegument acquisition by viral nucleocapsids during the late stage of virion assembly has been implicated.[@bb0330] [@bb0610] Leflunomide is effective against multidrug-resistant cytomegalovirus (CMV) in vitro,[@bb1425] although this in vitro activity is modest and the selectivity index is low.[@bb0340] This anti-CMV effect of leflunomide and FK778 was confirmed in a rat model of heterotopic heart transplantation.[@bb0220] [@bb1495] Another interesting feature is that both leflunomide and FK778 have vasculoprotective effects, independent of the inhibition of dihydroorotate dehydrogenase.[@bb0275] [@bb1085]

### Experimental Experience {#s0030}

In various rodent transplantation studies, leflunomide was shown to be at least equally potent as cyclosporine,[@bb0075] and able to synergize with cyclosporine to induce tolerance.[@bb0720] Specific characteristics of leflunomide-mediated immunosuppression in rats were its ability to interrupt ongoing acute rejections,[@bb1445] and its efficacy in preventing and treating chronic vascular rejection.[@bb1460]

One of the most attractive characteristics of leflunomide and the MNAs is their strong capacity to delay xenograft rejection and to induce partial xenograft tolerance.[@bb0715] This may be related to the strong suppressive effects of leflunomide on T-cell-independent xenoantibody formation, and on its capacity to induce natural killer cell non-responsiveness and to modulate xenoantigen expression.[@bb0195]

Monotherapy with FK778 in rats,[@bb0920] and its combination with microemulsified cyclosporine in dogs[@bb0650] or tacrolimus in non-human primates,[@bb0990] reduced chronic allograft nephropathy[@bb0920] and significantly prolonged renal allograft survival.[@bb0650] [@bb0920] [@bb0990]

### Clinical Experience {#s0035}

The main role of leflunomide in renal transplantation nowadays is the treatment of BK virus nephropathy (BKVN).[@bb0580] [@bb1440] Based on the in vitro effective anti-BK concentration, an in vivo target level of 50--100 mg/mL has been proposed. In a prospective study, 26 renal transplant recipients with biopsy-proven BKVN were treated with leflunomide in combination with discontinuation of MMF and reduction of tacrolimus to a 4--6 ng/mL range.[@bb1440] Although the leflunomide levels were in the lower range (on average 50 mg/mL), a significant reduction in serum and urine BKV titers was obtained, allograft function stabilized, and the overall graft loss rates because of BKV were only 15%.[@bb0580] Less encouraging results were obtained in another prospective open-label study in which viral clearance was only obtained in 40% of patients with significant toxicity, resulting in discontinuation of the drug in 17% of patients.[@bb0335] The contribution of reduction of immunosuppressive agents and leflunomide to the efficacy of BKVN treatment is unclear at this moment.[@bb0300] [@bb0575] [@bb1330] Based on recent in vitro data, it has been suggested that the combination of sirolimus with leflunomide might be an effective treatment approach.[@bb0705] FK778 has also been studied in the context of BKVN, but although it was able to decrease BK viral load, FK778 treatment was associated with more acute rejections, decreased renal function, and more adverse events compared with reduction of immunosuppression.[@bb0475]

In animal studies, leflunomide was able to reverse acute and chronic rejection. Two clinical studies reported that leflunomide was capable of stabilizing allograft function in patients with worsening allograft function due to chronic allograft dysfunction.[@bb0680]

A phase II multicenter study was performed with FK778 involving 149 renal transplant patients,[@bb1385] where FK778 was combined with tacrolimus and corticosteroids. The patients receiving FK778 experienced a reduced number of acute rejections, but there was no effect on graft survival at week 16.[@bb1385] The reduction of acute rejection episodes was most pronounced in the subgroup in which target levels were obtained in the second week. Of note, mean total and low-density lipoprotein cholesterol levels were 20% lower in the FK778 group versus the placebo group.[@bb1385] The validity of these results was hampered by the design of the study, and, at this time, the development of FK778 in the field of organ transplantation has ceased.

### Toxicity {#s0040}

Although rats tolerate leflunomide well, dogs readily develop anemia and gastrointestinal ulcerations. Reportedly, the most frequent side effects in arthritis patients receiving long-term leflunomide treatment were diarrhea (17%), nausea (10%), alopecia (8%), and rash (10%), leading to a dropout rate of ± 5%.[@bb1155] Recently, thrombotic microangiopathy attributed to leflunomide was reported in patients treated for BKVN.[@bb0680] In the above-mentioned phase II study involving FK778, there was a dose-dependent increase in side effects, including anemia, hypokalemia, symptomatic myocardial ischemia, and esophagitis.[@bb1385] Other reported side effects are pneumonitis and peripheral neuropathy.[@bb0200] [@bb0595] Leflunomide has teratogenic effects in both animals and humans, and a washout period with cholestyramine is advised for both women and men before considering conception.[@bb0890] Combining leflunomide with methotrexate might increase the risk for bone marrow suppression and liver toxicity.[@bb0240] [@bb1210] Furthermore, rifampin accelerates the conversion of leflunomide to teriflunomide, and might increase the levels. Combination with warfarin potentially increases the international normalized ratio.

### Conclusion {#s0045}

The role of leflunomide in renal transplantation is limited to the treatment of patients with BKVN and some promising results have been reported in this respect. The MNAs -- because of their shorter half-life -- were considered a promising class of immunosuppressants but results in randomized clinical trials have been disappointing, and the development of these agents in organ transplantation has been halted.

FTY720 or Fingolimod {#s0050}
--------------------

### Chemical Structure and Pharmacology {#s0055}

FTY720 or 2-amino-2-\[2-(4-octylphenyl)ethyl\]-1,3-propanediol hydrochloride is a synthetic structural analogue of myriocin, a metabolite of the ascomycete *Isaria sinclairii*, a type of vegetative wasp.[@bb0400] [@bb0405] [@bb1080] Maximal concentration and area under the curve are proportional to the dose, indicating that the pharmacokinetic profile of FTY720 is linear. The volume of distribution is largely superior to the blood volume, indicating a widespread tissue penetration. FTY720 undergoes hepatic metabolism and has a long half-life (around 100 hours).

### Mechanism of Action {#s0060}

FTY720 has a unique mechanism of action as it mainly affects lymphocyte trafficking.[@bb0195] [@bb0490] [@bb0775] [@bb0800] FTY720 acts as a high-affinity agonist of the sphingosine 1-phosphate receptor-1 (S1PR1 or Edg1). Binding of its receptor results in internalization of S1PR1, rendering lymphocytes unable to respond to the naturally occurring gradient of S1P (low concentrations in thymus and secondary lymphoid organs, high concentrations in lymph and plasma) retaining lymphocytes in the low-S1P environment of lymphoid organs.[@bb0800] [@bb0935] Following FTY720 administration in mice, B and T cells immediately leave the peripheral blood and migrate to the peripheral lymph nodes, mesenteric lymph nodes. and Peyer's patches. The cells return to the peripheral blood after withdrawal of the drug without undergoing apoptotic death.[@bb1490] This altered cell trafficking is accompanied by a reduction of lymphocyte infiltration into grafted organs.[@bb0485] [@bb1490] [@bb1500] Interestingly, lymphocytes treated ex vivo with FTY720 and reintroduced in vivo similarly migrate to the peripheral lymphoid tissues, indicating that FTY720 acts directly on lymphocytes. This process of accelerated homing was completely blocked in vivo by co-administration of anti-CD62L, anti-CD49d, and anti-CD11a monoclonal antibody.[@bb0195] In vitro, FTY720 in the presence of TNF-α increases the expression of certain intercellular adhesion molecules on human endothelial cells.[@bb0700] Thus, alteration of cell trafficking by FTY720 may result not only from its direct action on lymphocytes, but also from an effect on endothelial cells.

Interestingly, it has been suggested that CD4^+^CD25^+^ regulatory T cells are differently affected by FTY720 compared to T-effector cells.[@bb1090] CD4^+^CD25^+^ regulatory T cells express lower levels of S1P~1~ and S1P~4~ receptors and, hence, show reduced response to FTY720. Furthermore, in vitro FTY720-treated CD4^+^CD25^+^ T-regulatory cells possess an increased suppressive activity in an antigen-specific proliferation assay.[@bb1090] [@bb1505]

Unlike CNI, FTY720 is a poor inhibitor of T-cell function in vitro.[@bb1340] In particular, FTY720 does not influence antigen-induced IL-2 production. In vitro exposure to high FTY720 concentrations (4 × 10^--6^) induces chromatin condensation, typical DNA fragmentation, and formation of apoptotic bodies. Whether administration of FTY720 in vivo is also associated with significant apoptosis is a matter of debate.[@bb0195] [@bb0795]

S1PR are also present on murine dendritic cells. Upon administration of FTY720, dendritic cells in lymph nodes and spleen are reduced, the expression of CD11b, CD31/PECAM-1, CD54/ICAM-1, and CCR-7 is downregulated, and transendothelial migration to CCL19 is diminished.[@bb0665] In a recent study it was demonstrated that FTY720 inhibited lymphangiogenesis and thus prolonged allogeneic islet survival in mice.[@bb1480]

### Experimental Experience {#s0065}

FTY720 given daily by oral gavage has marked antirejection properties in mice, rats, dogs, and monkeys.[@bb0795] [@bb1250] [@bb1340] [@bb1475] FTY720 (0.1--10 mg/kg) prolongs survival of skin allografts in highly allogeneic rodent models.[@bb0190] In a DA to LEW rat combination, a short course of peritransplant oral FTY720 (5 mg/kg; days --1 and 0) prolongs cardiac allograft survival and is as efficient as a 10-day posttransplant treatment with tacrolimus at 1 mg/kg.[@bb1465] Cardiac and liver allograft survival is prolonged in the ACI to Lew rat model by either induction or maintenance treatment with FTY720.[@bb1240] Even delayed administration of FTY720 interrupts an ongoing allograft rejection, suggesting a role for FTY720 as a rescue agent.[@bb1245] [@bb1470] FTY720 blocks not only rejection but also graft-versus-host disease after rat intestinal transplantation.[@bb0820] FTY720 may also protect form ischemia-reperfusion injury, partially through its cytoprotective actions.[@bb0265] [@bb0415] [@bb0770] [@bb1215]

Both small- and large-animal models provide evidence that FTY720 acts in synergy with CNI, and that this benefit does not result from pharmacokinetic interactions.[@bb1245] An induction course with FTY720 acts in synergy with posttransplant tacrolimus in prolongating cardiac allograft survival in rats.[@bb1470] A similar phenomenon has been observed when FTY720 is used posttransplant in combination with cyclosporine in rat skin and heart allografts.[@bb0515] [@bb1245] FTY720 shows synergistic effect with CNI in heart and liver transplant in the ACI to Lew rat model.[@bb1475] FTY720 shows synergy with cyclosporine in dog kidney (0.1--5 mg/kg/day) and monkey kidney (0.1--1 mg/kg/day) transplantation.[@bb1340] Finally, FTY720 (0.1 mg/kg) synergizes with CNI in dog liver transplantation.[@bb1255] Synergy between FTY720 and rapamycin was also observed in rat cardiac transplantation.[@bb1435]

KRP-203 or 2-amino-2-(2-\[4-3(-benzyloxyphenylthio)-2-cholorophenyl\]ethyl)-1,3-propanediol hydrochloride has a similar molecular structure as FTY720. KRP-203 alone or in combination with low-dose cyclosporine or MMF prolonged skin, heart, and renal allograft survival.[@bb0395] [@bb1125] [@bb1235]

### Clinical Experience {#s0070}

Stable renal transplant patients maintained on cyclosporine tolerate well one oral dose of FTY720 (0.25--3.5 mg). Similarly to its effect in animals, single doses of FTY720 cause a lymphopenia that is dose-dependent in intensity and duration, and that equally affects CD4 cells, CD8 cells, memory T cells, naïve T cells, and B cells.[@bb0150]

In phase II and III studies in de novo renal transplantation, it was shown that 2.5 mg FTY720 in combination with full-dose cyclosporine and steroids is as effective as MMF in combination with full-dose cyclosporine and steroids, although the FTY720-treated patients had lower creatinine clearance at 12 months.[@bb1305] [@bb1310] FTY720 5 mg did not allow a 50% reduction in cyclosporine exposure.[@bb1075] [@bb1305] FTY720 2.5 mg in combination with reduced-dose cyclosporine resulted in underimmunosuppression.[@bb0830] Also in combination with tacrolimus, FTY720 2.5 mg was not superior to MMF in a recent study in de novo renal transplant recipients.[@bb0505] Recently, it was reported that FTY720 in combination with everolimus was not beneficial with regard to prevention of acute rejection and preservation of allograft function in renal transplant recipients at high risk for delayed graft function.[@bb1300]

### Toxicity {#s0075}

The side effects of FTY720 are in general similar to those of other immunosuppressants, with hypertension, anemia, constipation, and nausea most commonly reported. Side effects specific for FTY720 are bradycardia, macular/retinal edema, dyspnea, and a transient rise in liver function tests.[@bb0830] [@bb1075] Although it is considered a main impediment of further clinical development, reduction of heart rate after the first dose of FTY720 is transient and does not persist in the maintenance phase.[@bb0310] [@bb0885] Importantly, typical side effects of CNI -- nephrotoxicity, neurotoxicity, and diabetogenicity -- have not been observed with FTY720.

### Conclusion {#s0080}

FTY720 has a unique mechanism of action. The available clinical studies show that FTY720 is not superior to standard care and therefore its future in organ transplantation is uncertain.

1,25-Dihydroxyvitamin D~3~ and its Analogues {#s0085}
--------------------------------------------

### Chemical Structure and Pharmacology {#s0090}

1,25-Dihydroxyvitamin D~3~ (1,25(OH)~2~D~3~) and some of its new synthetic structural analogues are promising immunomodulators with effects in autoimmunity and transplantation immunology. Besides its well-known role in mineral and bone homeostasis, non-classical effects of vitamin D have been increasingly recognized, such as modulation of growth, differentiation, and function of various cell types, regulation of immune responses, cardiovascular processes, and cancer prevention.[@bb0105] [@bb1390] Local vitamin D metabolism allows immune cells to modulate immune response autonomously. Optimal immune functioning of this autocrine and/or paracrine circuit crucially depends on the availability of circulating 1,25(OH)~2~D~3~. The exact levels of circulating 1,25(OH)~2~D~3~ needed to meet the requirements of "vitamin D sufficiency" are still a matter of debate, especially in the light of the non-classical effects of vitamin D.

### Mechanism of Action {#s0095}

A role for 1,25(OH)~2~D~3~ in immune regulation is suggested by the presence of its receptor (vitamin D receptor or VDR) in almost all immune cells, including activated CD4 and CD8 cells, B cells, neutrophils, and antigen-presenting cells, hence modulating both innate and adaptive immune responses.[@bb0985] [@bb1260] Moreover, the VDR expression in some immune cells is controlled by immune signals.[@bb0055] Furthermore, most immune cells express vitamin D metabolizing enzymes such as CYP27B1 in T and B lymphocytes, and CYP2R1 in dendritic cells.[@bb0895] [@bb1185] This allows for the local conversion of 25(OH)D~3~ into 1,25(OH)~2~D~3~, and represents an important mechanism by which immune cells can reach supraphysiological levels of 1,25(OH)~2~D~3~ needed to influence immune responses without affecting systemic levels of 1,25(OH)~2~D~3~. Furthermore, the expression of CYP27B1 in immune cells is controlled by immune signals. For example, CYP27B1 expression by monocytes/macrophages is upregulated by interferon-γ (IFN-γ), lipopolysaccharide, *Mycobacterium tuberculosis*-derived 19 kDa lipoprotein and viral infections. Moreover, CYP27B1 expression in macrophages and dendritic cells is not suppressed by 1,25(OH)~2~D~3~ itself, allowing for massive local production of 1,25(OH)~2~D~3~ by macrophages in patients with granulomatous diseases. As an alternative negative-feedback loop 1,25(OH)~2~D~3~ upregulates CYP24 in immune cells.[@bb0285]

Upon exposure to 1,25(OH)~2~D~3~ monocytes acquire phenotypical features of macrophages, and macrophages obtain increased chemotactic and phagocytic activities.[@bb0460] Moreover, Toll-like receptor activation of monocytes/macrophages results in upregulation of VDR and VDR target genes leading to the induction of cathelicidin antimicrobial peptide and killing of *Mycobacterium tuberculosis*.[@bb0725] 1,25(OH)~2~D~3~ inhibits dendritic cell maturation (decreased levels of major histocompatibility complex class II and costimulatory molecules), enhances endocytic capacity, inhibits the production of IL-12 and IL-23, and enhances the release of IL-10 and macrophage inflammatory protein-3α. Dendritic cells are thereby deviated towards a more immature or tolerogenic phenotype, having in vitro as well as in vivo the capacity to induce the development of regulatory T cells.[@bb0450] [@bb0945] [@bb1380]

Upon T-cell activation, VDR expression is dramatically increased. Furthermore, 1,25(OH)~2~D~3~ also directly alters the cytokine profile of T cells by inhibiting the production of inflammatory Th1-cytokines such as IL-2 and IFN-γ, as well as the Th17-derived cytokines IL-17 and IL-21.[@bb0560] [@bb1290] CD4^+^CD25^high^CD127^low^ regulatory T cells were induced after vitamin D exposure and IL-10 was selectively induced within CD4 T cells. The molecular pathways by which 1,25(OH)~2~D~3~ modulates the expression of these and other genes in the immune system varies widely (reviewed in reference [@bb0060]). Next to the classical interaction with VDR-specific binding sites in the promoter region of target genes (vitamin D-responsive elements), as in the inhibition of IFN-γ,[@bb0230] 1,25(OH)~2~D~3~ also interferes with other pathways of transcription regulation. For example, 1,25(OH)~2~D~3~-mediated inhibition of IL-2 is due to impairment of nuclear factor of activated T cells/activating protein-1 (AP-1) complex formation and subsequent association with its binding site within the IL-2 promoter.[@bb0030] [@bb1270]

Exposing B cells to 1,25(OH)~2~D~3~ inhibits the proliferation, plasma cell differentiation, immunoglobulin secretion (IgG and IgM), and memory B-cell generation, and induces B-cell apoptosis.[@bb0185] Finally, 1,25(OH)~2~D~3~ was put forward as an important regulator of lymphocyte trafficking. Active 1,25(OH)~2~D~3~ imprints activated T cells and terminally differentiating B cells with skin-homing properties via induction of the skin-homing receptor CCR10.[@bb1130] [@bb1150]

### Experimental Experience {#s0100}

The fact that 1,25(OH)~2~D~3~ and its analogues influence the immune system by immunomodulation through the induction of immune shifts and regulator cells makes these products very appealing for clinical use, especially in the treatment and prevention of autoimmune diseases. In the NOD mouse, upregulation of regulator cells and a shift away from Th1 towards Th2 could be observed in 1,25(OH)~2~D~3~-treated mice, both locally in the pancreas as well as in the peripheral immune system.[@bb0455] [@bb0900] Moreover, a restoration of the defective sensitivity to apoptosis characteristic for NOD T lymphocytes was observed, resulting in a better elimination of autoreactive effector cells.[@bb0170] [@bb0260] This increased sensitivity to apoptosis has been described for different apoptosis-inducing signals. This mechanism may explain why an early and short-term 1,25(OH)~2~D~3~ treatment before the clinical onset of autoimmunity can lead to long-term protection and restoration of self-tolerance.

A clear additive and even synergistic effect was observed between 1,25(OH)~2~D~3~ or its analogues and other more classical immunosuppressants such as cyclosporine, sirolimus, or MMF, both in vitro and in several in vivo autoimmune disease models, such as autoimmune diabetes[@bb0175] [@bb0480] and experimental autoimmune encephalomyelitis.[@bb0135] [@bb0140] [@bb1365]

Moreover, 1,25(OH)~2~D~3~ and its analogues were investigated in various transplantation models such as pancreatic islet allo- and xenotransplantation in mice,[@bb0450] [@bb0480] allogeneic heart[@bb0570] and skin transplantation in mice,[@bb0095] [@bb1395] allogeneic aorta,[@bb1000] bone marrow,[@bb0905] heart,[@bb0535] [@bb0685] kidney,[@bb1010] and liver transplantation in rats.[@bb1015] The overall conclusion that can be drawn from these studies is that, as monotherapy, 1,25(OH)~2~D~3~ and its analogues provoke only a modest prolongation of graft function. This is not surprising in view of the rather weak intrinsic effects of 1,25(OH)~2~D~3~ and its analogues on T cells. However, in conjunction with other immunosuppressants, strong synergistic effects often can be observed. In addition, in view of its effect on antigen presentation and on directing the immune system in the Th2 direction, 1,25(OH)~2~D~3~ may help to induce tolerance.[@bb0450]

### Clinical Experience {#s0105}

Multiple groups have reported a correlation between vitamin D deficiency and susceptibility to respiratory infections, especially in the context of infections by *Mycobacterium tuberculosis* and Gram-negative bacteria.[@bb0530] Autier and Gandini performed a meta-analysis including 18 independent randomized controlled trials, demonstrating that administration of vitamin D supplementation is associated with a decrease in overall mortality rates (relative risk 0.93, 95% confidence interval 0.87--0.99).[@bb0050] There is still a lack of non-biased large cohort studies that can sustain the proposed benefits of vitamin D supplementation for optimal immune function.

Mutations in the CYP2R1 gene, as well as in the CYP17B1 gene, impairing their enzymatic activity, have been described and polymorphisms in these genes have been proposed to be associated with type 1 diabetes mellitus susceptibility.[@bb0735] [@bb1005] Analogues of vitamin D could successfully block progression of insulitis in prediabetic NOD mice, along with preventing recurrence of autoimmune diabetes in NOD mice after syngeneic islet transplantation, when combined with other immunomodulating agents.[@bb0175] [@bb0450]

### Toxicity {#s0110}

A major concern remains the side effects of 1,25(OH)~2~D~3~ on calcium and bone metabolism. The use of 1,25(OH)~2~D~3~ analogues which have maintained or amplified immunomodulatory effects in combination with reduced effects on calcium and bone partially conquer this problem.[@bb1370] The additional use of calcium-lowering conditions, such as limited nutrient calcium intake, and bone resorption inhibitors, such as bisphosphonates, aid in further bypassing the negative side effects of hypercalcemia and excessive bone resorption,[@bb1360] thereby facilitating the step towards the clinical applicability of 1,25(OH)~2~D~3~ and its analogues for their potent immunomodulatory properties.

### Conclusion {#s0115}

With the discovery of VDRs and vitamin D-metabolizing enzymes in immune cells, it is now evident that 1,25(OH)~2~D~3~ exerts a plethora of effects targeting both the innate and adaptive immune compartment. The emerging data linking inadequate vitamin D levels to immune anomalies, such as increased infection rates and autoimmunity, are of interest in this context. VDR agonists, and especially hypocalcemic vitamin D analogues, are plausible candidates for the prevention and/or treatment of infections such as tuberculosis and several autoimmune disorders.

Bredinin or Mizoribine {#s0120}
----------------------

### Chemical Structure and Pharmacology {#s0125}

Bredinin, 4-carbamoyl-1-ß-[d]{.smallcaps}-ribofurano-syhmidazolium-5-olate, is a nucleoside analogue that is structurally similar to ribavirin. It was first isolated from the culture media of the ascomycetes *Eupenicillium brefeldianum* harvested from the soil of Hachijo Island (Japan, 1971). It has weak antibiotic activity against *Candida albicans*.[@bb0825]

### Mechanism of Action {#s0130}

Bredinin exerts its immunosuppressive function through selective inhibition of the enzymes inosine monophosphate dehydrogenase and guanosine monophosphate synthetase, both of which are required for the generation of guanosine monophosphate from inosine monophosphate in the de novo pathway. In contrast to azathioprine, bredinin is not incorporated into nucleic acids in the cells, resulting in fewer side effects, such as myelosuppression and hepatoxicity. Bredinin was found to inhibit both humoral and cellular immunity by selectively inhibiting lymphocyte proliferation.[@bb0545]

### Experimental and Clinical Experience {#s0135}

In a canine model of renal transplantation, bredinin prolonged graft survival. In humans, as compared to azathioprine, bredinin showed equally potent immunosuppressive activity and fewer adverse effects.[@bb0045] [@bb0615] [@bb1275] [@bb1285] As expected based on its similarity in structure to ribavirine, bredinin exhibits in vitro antiviral activity against CMV, respiratory syncytial virus, measles, hepatitis C, corona virus, parainfluenza, and influenza virus.[@bb0520] [@bb0850] [@bb1055] [@bb1120] In a recent study, bredinin was substituted for MMF in patients with BKV in their urine. BKV DNA in the urine became negative in five out of seven patients.[@bb0420] In the remaining two patients, there was a significant decrease in urinary BKV DNA. No acute rejection or deterioration of graft function occurred during the study period.[@bb0420]

### Toxicity {#s0140}

The principal adverse reactions associated with the use of bredinin were leukopenia, abnormal hepatic function, rash, increased levels of uric acid, and vomiting.

### Conclusion {#s0145}

Bredinin has mainly been used in Japan and is infrequently used elsewhere. As a consequence, experience with bredinin is limited, but results show that it is a safe and effective immunosuppressant in human kidney transplantation. Because of its antiviral activity, bredinin might be yet another drug to be evaluated in the setting of BKVN.

JAK3 Inhibitors: CP-690,550, Tasocitinib, or Tofacitinib {#s0150}
--------------------------------------------------------

Several JAK3 inhibitors have been developed, e.g., tyrphostin AG-490, PNU156804, dimethoxyquinazoline compounds (WHI-P131), CP-690,550 and Mannich base NC1153, and several of them have been shown to possess immunosuppressive properties.[@bb0090] [@bb0600] [@bb0635] [@bb1180] Given the lymphocyte-restricted role of JAK3, JAK3 inhibitors are considered an interesting novel class of immunosuppressive drugs.

### Chemical Structure and Pharmacology {#s0155}

Of the multiple potential candidate compounds, one has entered clinical trials -- the ATP congener CP-690,550 (CP; tasocitinib or tofacitinib, Pfizer, NJ), which binds to the ATP catalytic site on JAK molecules. It has been proposed that analysis of P-STAT5 at the cellular level could be an adequate means to monitor the immunomodulatory effect of CP-690,550.[@bb0995]

### Mechanism of Action {#s0160}

JAK3 is a tyrosine kinase essential for the signal transduction from the common gamma-chain of the cytokine receptors for IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21 to the nucleus. As the expression of the receptors is restricted to immune cells, this makes them an attractive target for new immunosuppressants. Signal transduction mediated by JAK3 is obligatory for lymphocyte activation, differentiation, and homeostasis, as evidenced by the finding that deficiency in JAK3 results in severe combined deficiency syndrome.[@bb0745] [@bb1025] [@bb1035] [@bb1040] A possible detrimental effect of interference with IL-2 signaling relates to the fact that tolerance induction is essentially dependent on the IL-2 pathway.[@bb0645] [@bb0760] [@bb0765] Thus, the challenge for immunosuppressive drug design has been to achieve selective inhibition of JAK3 versus JAK2 activities. Although Pfizer claimed a 20-fold selectivity for JAK3 using an in vitro assay, clinical data suggest that this ratio is far less than 20-fold. This narrow selectivity was confirmed by the work of Karaman et al.[@bb0590]

### Experimental Experience {#s0165}

CP-690,550 is the most potent (inhibitory potency of 1 nM) and selective JAK3 inhibitor developed to date. In both rodents and non-human primates, CP-690,550 exerted strong suppression of immune reactions and prolonged the survival of cardiac and renal allografts. In monotherapy it significantly delayed the onset of rejection in kidney allografts.[@bb0125] [@bb0130] [@bb0180] In non-human primates, CP-690,550 significantly reduced IL-2-enhanced IFN-γ production and CD25 and CD71 expression by T cells. Furthermore, CP-690,550 inhibited cellular alloimmune responses in vitro.[@bb0180] [@bb0925] Administration in vivo resulted in a reduction of NK cell and T-cell numbers, whereas CD8 effector memory T-cell levels were unaltered.[@bb0235] [@bb0925] Recently, it was shown that CP-690,550 selectively inhibits T-cell effector function while preserving the suppressive activity of CD4^+^CD25^high^ regulatory T cells.[@bb1115]

### Clinical Experience {#s0170}

CP-690,550 was evaluated as induction and maintenance therapy in a phase IIA, multicenter, open-label, randomized controlled trial in kidney transplant recipients.[@bb0160] All patients received induction therapy, MMF, and steroids. Patients in group 1 received tacrolimus, while patients in groups 2 and 3 were administered CP-690,550 15 mg and 30 mg twice a day, respectively.[@bb0160] Because of the high incidence of BKVN in the CP-690,550 groups, the protocol was adjusted to stop MMF and decrease the steroid exposure. Compared to tacrolimus, both CP-690,550 groups showed similar rates of acute rejection episodes and allograft function, but experienced greater incidences of hyperlipidemia and infections (suggestive of additional JAK2 inhibition).[@bb0160] A phase IIB trial compared cyclosporine at standard dosage versus CP-690,550 15 mg twice a day for 6 months then 10 mg twice a day, or CP-690,550 15 mg twice a day for 3 months then 10 mg twice a day. All patients received in addition induction therapy, MMF, and steroids. Unexpectedly, the lower CP-690,550 dosage arm showed a trend toward the lowest rejection rate and a superior allograft function. However, in this study there were important adverse events, including increased CMV infection rates, and BKVN in both CP-690,550 arms (data presented at 2011 American Transplant Congress).

### Toxicity {#s0175}

In a dose escalation study, the most frequent adverse events were infection and gastrointestinal side effects. CP-690,550 15 mg and 30 mg twice a day were associated with a mean decrease in hemoglobin from baseline of 11%.[@bb1375] There was in addition a decrease in natural killer cells and B cells. There were no changes in the number of neutrophils, total lymphocytes, platelets, or CD4 or CD8 T cells.[@bb1375]

### Conclusion {#s0180}

In summary, combination of CP-690,550 with MMF resulted in acceptable rates of acute rejection with evidence of overimmunosuppression when CP-690,550 30 mg twice a day was combined with MMF. CP-690,550 15 mg twice a day co-administered with MMF resulted in similar outcomes while associated with modest lipid elevations and a higher rate of viral infections. In our opinion, considering the known side-effect profile of CNI, further evaluation of CP-690,550 is warranted. Given the side effects reported with the use of CP-690,550, the challenge remains to develop immunosuppressive drugs with truly selective inhibition of JAK3 versus JAK2 activities. The lack of success in developing a selective antagonist of JAK3 probably relates to the focus on chemical analogues of ATP while more success is to be expected from developing molecules displaying allosteric inhibition via binding of non-catalytic sites.

AEB071 or Sotrastaurin {#s0185}
----------------------

### Chemical Structure and Pharmacology {#s0190}

Sotrastaurin (AEB071) is a low-molecular-weight, synthetic compound that potently and reversibly inhibits all 10 isoforms of protein kinase C (PKC) -- most importantly, PKC-θ, PKC-α, and PKC-β, with lesser activity on PKC-δ.[@bb0620] Sotrastaurin is primarily metabolized through hepatic CYP3A4 into inactive metabolites and *N*-desmethyl-sotrastaurin, which has similar potency as sotrastaurin and is present at low blood concentrations (less than 5% of the parent exposure). Renal excretion of sotrastaurin is negligible and only a small amount is excreted in the bile (1% of the dose). The elimination half-life of sotrastaurin averages 6 hours. In clinical trials, it is recommended that patients administer sotrastaurin consistently either with or without food to avoid food-related fluctuations in drug exposure over time.[@bb0620]

Clinical drug interaction studies to date have demonstrated that sotrastaurin increases the area under the concentration--time curve of everolimus (1.2-fold) and of tacrolimus (2-fold).[@bb0625] Sotrastaurin increased tacrolimus concentration inasmuch as the tacrolimus dose needed to achieve a given *C* ~0~ was up to 47% lower when combined with sotrastaurin versus MMF.[@bb0625] Conversely, sotrastaurin area under the concentration--time curve is increased up to 1.8-fold by cyclosporine and 4.6-fold by ketoconazole.[@bb0630]

### Mechanism of Action {#s0195}

PKC is a family of serine/threonine-specific protein kinases involved in diverse signal transduction pathways that modulate a whole range of cellular processes, including activation, proliferation, differentiation, apoptosis, and autophagy.[@bb1160] PKC-θ has been shown to be essential in the T-cell receptor/CD3 signal transduction pathway. PKC-α modulates Th1 responses, including IFN-γ production. PKC-β controls B-cell receptor-induced NF-κB transactivation and T-independent B-cell responses. Finally, PKC-ε influences macrophage function.[@bb0810] [@bb1280]

### Experimental Experience {#s0200}

Of note, sotrastaurin was demonstrated to be non-toxic when added to human islet cultures.[@bb0815] These results suggest AEB071 to be an appropriate immunosuppressive candidate for clinical trials in islet transplantation. Recently, it was shown in non-human primates that sotrastaurin in combination with cyclosporine at subtherapeutic doses resulted in markedly prolonged renal allograft survival, indicating synergistic immunosuppressive effects.[@bb0100]

### Clinical Experience {#s0205}

In a phase II randomized controlled trial, sotrastaurin with standard or reduced tacrolimus was compared with standard tacrolimus alone, in addition to induction therapy and steroids.[@bb0155] Three months posttransplant, stable patients on sotrastaurin were switched from tacrolimus to MMF. The three arms showed equal efficacy up to 3 months; at the end of the study there was no difference in allograft function, although the incidence of acute rejection was significantly higher in the standard tacrolimus with sotrastaurin arm.[@bb0155] Because of lack of efficacy, this study was prematurely discontinued. In another recent trial in de novo renal transplant recipients with immediate graft function, study subjects were randomized to sotrastaurin or tacrolimus.[@bb0370] All patients received basiliximab, MMF, and steroids. This study demonstrated a lower degree of efficacy but better renal function with the CNI-free regimen of sotrastaurin with MMF versus the tacrolimus-based control.[@bb0370] A study combining sotrastaurin with everolimus is currently ongoing.

### Toxicity {#s0210}

In the above-mentioned clinical trial, there was a 12% incidence of tachycardia and 18% of serious infections.[@bb0155] [@bb0370] A dose-dependent chronotropic effect has been observed in preclinical and phase I sotrastaurin studies; therefore the higher heart rate and tachycardia observed with the sotrastaurin in combination with MMF were not unexpected. All tachycardia adverse events were mild and the majority occurred soon after transplantation.

### Conclusion {#s0215}

Sotrastaurin blocks PKC-mediated early T-cell activation,[@bb0105] providing a new approach for immunosuppression distinct from CNI. However, the efficacy results of this phase II study do not support the combination of sotrastaurin 300 mg twice a day with MMF as a CNI-free regimen. Based on the results recently reported by Bigaud et al. in non-human primates,[@bb0100] sotrastaurin as a CNI-sparing agents warrants further evaluation in future clinical trials.

Bortezomib {#s0220}
----------

### Chemical Structure and Pharmacology {#s0225}

Bortezomib is a proteasomal inhibitor approved by the Food and Drug Administration for the treatment of multiple myeloma. Bortezomib is increasingly used in the setting of solid-organ transplantation. Bortezomib was administered in four doses of 1.3 mg/m^2^ intravenously in 3-5-minute infusions over an 11-day period in kidney transplant recipients. Prior to bortezomib administration, patients need to be premedicated with methylprednisolone. Peak serum concentration is reached at 30 minutes and the drug is cleared within 1 hour.[@bb0315]

### Mechanism of Action {#s0230}

Bortezomib is a selective inhibitor of the 26S proteasome, preventing the activation of NF-κB.[@bb1225] It induces apoptosis of rapidly dividing, metabolically active cells with extensive protein synthesis. The ability of bortezomib to target plasma cells spurred interest as a new therapeutic approach in the treatment or prevention of alloantibody formation in organ transplantation.

### Experimental Experience {#s0235}

In vitro, bortezomib was associated with a reduction in the number of bone marrow-derived plasma cells and attenuated alloantibody production.[@bb0970] Bortezomib primarily acts through plasma cell depletion, resulting in reduced antibody production to T-dependent antigens. As marginal zone B cells are resistant to bortezomib-mediated effects, T-independent type 2 responses are less affected.[@bb0670] In a mouse model of lupus, bortezomib depleted both short- and long-lived plasma cells, resulting in a reduction of anti-double-stranded DNA antibody production.[@bb0855] Vogelbacher et al. recently established that bortezomib alone or in combination with sirolimus can also prevent alloantibody formation in a rat model of kidney transplantation.[@bb1400]

### Clinical Experience {#s0240}

Bortezomib therapy for antibody-mediated rejection has resulted in mixed results.[@bb0280] [@bb0320] [@bb1095] Everly et al. administered bortezomib to 6 patients with antibody-mediated rejection with concomitant acute cellular rejection refractory to currently available therapies.[@bb0320] Bortezomib administration resulted in resolution of antibody-mediated rejection in all 6 patients, a decrease of donor-specific antibody levels, and improvement of allograft function.[@bb0320] In another study, Walsh et al. reported the results of bortezomib treatment in 28 patients with antibody-mediated rejection.[@bb1430] Bortezomib treatment was associated with variable results, with better responses in early (occurring in the first 6 months after transplantation) versus late (occurring 6 months or more after transplantation) antibody-mediated rejection.[@bb1430] In contrast, in the study of Sberro-Soussan et al., bortezomib treatment did not result in a decrease of donor-specific antibody mean fluorescence intensity when used as sole desensitization therapy in four renal transplant recipients with subacute antibody-mediated rejection with persistent donor-specific antibodies.[@bb1095] However, in this study bortezomib therapy was not initiated until weeks or months following the diagnosis of antibody-mediated rejection, and repeat biopsies were not performed following bortezomib treatment.[@bb1095]

### Toxicity {#s0245}

The most common side effects associated with bortezomib treatment are gastrointestinal toxicity, thrombocytopenia, and neuropathy.[@bb0320] These can be potentially severe and disabling. To date, no increase in rate of opportunistic infections has been reported. Importantly, although bortezomib is associated with substantial reductions in donor-specific antibody levels, it does not result in a decrease in protective antibody levels.[@bb0325]

### Conclusion {#s0250}

Proteasome inhibitor therapy has potential in the treatment of antibody-mediated rejection in kidney transplant recipients both as primary and rescue therapy. Optimal responses with bortezomib are obtained when antibody-mediated rejection occurs early posttransplant and bortezomib treatment is initiated promptly. Bortezomib has recently also been shown to provide effective therapy for antibody-mediated rejection in heart and lung transplant recipients.[@bb0290] [@bb0860]

Others {#s0255}
------

Cladiribine is an adenosine deaminase-resistant analogue of deoxyadenosine and is used in the treatment of leukemia and lymphoma. A number of studies have explored the immunosuppressive capacity of cladiribine. In vitro, cladribine inhibits both B- and T-cell proliferation.[@bb0435] In vivo, cladiribine monotherapy was shown to prolong skin allograft survival in mice,[@bb0440] in combination with cyclosporine it prolonged liver and heart allograft survival in rats,[@bb1110] and was more effective than cyclosporine monotherapy in small-bowel allografts.[@bb0875] However, no clinical trials are published to date.

The farnesyltransferase inhibitor A 228839 was developed as an anticancer compound that inhibits Ras GTPases. A 228839 inhibited lectin-induced proliferation and antigen-presenting cell-induced T-cell proliferation. The compound also inhibited lymphocyte Th1 cytokine production and promoted apoptosis in lectin-activated lymphocytes.[@bb1140] Another farnesyltransferase inhibitor, ABT-100 was shown in vitro to block the secretion of IFN-γ and IL-4 by naïve T cells and suppressed alloreactivity. In a rat heterotopic cardiac transplant model, ABT-100 alone or in combination with subtherapeutic dose of cyclosporine delayed the development of acute rejection.[@bb1135] Given its combined antirejection and antioncogenic effects, farnesyltransferase inhibitors could represent an attractive new class of immunosuppressants in malignancy-prone organ transplant recipients if future clinical trials confirm their efficacy.

When a T-cell receptor recognizes its specific antigen the lymphoid cell-specific kinase lck is phosphorylated and, together with the receptor-associated CD3 complex, phosphorylates zinc-associated phosphorylase 70. These events trigger the downstream cascade that increases intracellular calcium, activating calcineurin. Inhibitors of lck have become available recently. A-770041 and structurally similar molecules have been shown to prolong the survival of heterotopic murine heart and renal subcapsular islet grafts as well as to blunt the production of immunoglobulin IgG2a. Emodin (C~15~H~10~O~5~), the cyclic derivative from rhubarb root and rhizomes, has been shown to prolong murine skin graft survival and to dampen IL-2 production.[@bb0730] However, neither of these archetypal compounds shows sufficient specificity for lck versus other kinases to warrant clinical development.[@bb1140]

FR 252921, an immunosuppressive agent isolated from the culture of *Pseudomonas fluorescens*, inhibits AP-1 transcription activity, and acts predominantly against antigen-presenting cells. FR 252921 demonstrated synergy with tacrolimus in vitro and in vivo. In murine models of skin transplantation, compared with the optimal dose of tacrolimus alone, the combination of FR 252921 and tacrolimus prolonged graft survival.[@bb0380], [@bb0385], [@bb0390]

Brequinar sodium exerts its immunosuppressive effects through the inhibition of the enzyme dihydroorotate dehydrogenase, resulting in inhibition of both T and B lymphocytes. Although the characteristics of brequinar suggest that it would be an attractive immunosuppressant, the suboptimal pharmacologic profile jeopardizes its use in transplant patients. The future use of this drug in the field of transplantation will require the development of analogues exhibiting a shorter half-life and reduced toxicity.

Spergualin was originally isolated from the culture filtrate of *Bacillus laterosporus,* and explored as a new anticancer or antibiotic substance. Its analogue 15-deoxyspergualin subsequently became widely known as a promising new immunosuppressant. The precise mode of action of 15-deoxyspergualin is largely unknown and, because of its poor oral bioavailability, 15-deoxyspergualin must be delivered parenterally, which hampers its widespread clinical use.[@bb1320] Its efficacy has been demonstrated in the treatment of kidney allograft rejection, ABO-incompatible kidney transplantation, and transplantation in sensitized patients.[@bb0035] [@bb0470] [@bb1265] Until analogues are developed that allow oral administration,[@bb0675] the major clinical indication of 15-deoxyspergualin is limited to the treatment of rejection crises where 15-deoxyspergualin may be an interesting alternative to steroids or antilymphocyte agents. The fact that it remains effective after recurrent administration is promising.

Upon cellular uptake, cyclophosphamide is extensively metabolized into its active compounds phosphoramide mustard and acrolein.[@bb0115] [@bb0250] The reaction of the phosphoramide mustard with DNA results in cell death.[@bb0255] Because of its limited efficacy and multiple side effects, the only standard indication for cyclophosphamide in transplantation today is the desensitization of highly sensitized recipients prior to kidney transplantation.[@bb0010] Most of these protocols involve repeated plasmapheresis, in combination with cyclophosphamide, either with or without continuation of steroids, until a kidney transplant becomes available.

TOTAL LYMPHOID IRRADIATION {#s0260}
==========================

For several decades, total lymphoid irradiation (TLI) has been used for the treatment of Hodgkin's disease. The possibility of applying TLI as an immunosuppressive regimen rather than an anticancer treatment was discovered by investigators at Stanford University.[@bb0410]

Procedure {#s0265}
---------

TLI is delivered through two ports. A first so-called mantle port includes the lymph nodes of the neck, axilla, and mediastinum. The other port is called the "inverted Y" and encompasses aortic, iliac and pelvic lymph nodes, and spleen. Usually, a total dose of 40--50 Gy (1 Gy = 100 rad) is administered in daily fractions of 1.5--2.5 Gy.

Mechanisms of Action {#s0270}
--------------------

Much of the currently available experimental evidence on the immunological mechanisms underlying TLI-induced tolerance points to the importance of suppressor cells. The group of Strober identified post-TLI suppressors cells as host-type natural killer T cells, as the protective effect of TLI against graft-versus-host disease was abrogated in mice with a CD1d inactivated gene.[@bb0655] These host-type natural killer T cells produced IL-4 and stimulated donor-type cells to produce IL-4 also.[@bb0655] [@bb0660] Definitive evidence of the functional importance and activity of these suppressor cells was delivered by the demonstration that they could prevent graft-versus-host disease in vivo.[@bb0500] Post-TLI attenuation of effector T-lymphocyte reactivity was equally proposed to be responsible for the observed immunosuppressed state after TLI.[@bb0085] [@bb0345] [@bb0350] This intrinsic T-cell defect was dependent on the irradiation of both thymus and extrathymic tissues.[@bb0910] After TLI, anergized T cells were shown to be incapable of proliferating even in the presence of exogenous IL-2.[@bb0360] In other studies, TLI was shown to lead to thymic clonal deletion of donor- or host-reactive lymphocytes.[@bb1060] TLI-treated mice also exhibited decreased antidonor cytotoxic T-cell precursor frequencies.[@bb0365] Finally, Strober's group showed that Th2 lymphocytes recover soon after TLI, whereas Th1 lymphocytes remain deficient for several months,[@bb0080] and showed that this defect can also be prevented by thymic shielding during irradiation.[@bb0085] This Th2 dominance after TLI has been confirmed by other groups in rodents[@bb0355] and in large animals.[@bb1170] Recently, Nador et al. demonstrated that tolerance induction after conditioning with TLI and antithymocyte globulin (ATG) depends upon the ability of naturally occurring regulatory natural killer T cells and regulatory T cells to suppress the residual alloreactive T cells that are capable of rejecting the allograft.[@bb0840]

Experimental Experience {#s0275}
-----------------------

TLI-treated BALB/c mice receiving fully allogeneic C57BL6 bone marrow and skin graft on the first day after TLI became stable hematopoietic chimeras without signs of graft-versus-host disease, and developed permanent donor-specific tolerance with preserved anti-third-party reactivity.[@bb1200] Tolerance induction was critically dependent on the width of the irradiation field, the time of transplantation after TLI, the total dose of TLI, and the absence of presensitization.[@bb1200] [@bb1405] [@bb1410]

Although bone marrow chimerism could be easily induced, tolerance to either heart[@bb0445] or kidney allografts[@bb0525] was not obtained, suggesting that TLI-induced bone marrow chimerism does not necessarily create tolerance toward organ-specific antigens.

The combination of TLI and low-dose cyclosporine was found to be effective and clinically safe in rats,[@bb1045] and TLI with postoperative ATG induced permanent and specific transplantation tolerance toward heart allografts in about 40% of transplanted dogs.[@bb1195] These encouraging results led to a similar trial in clinical kidney transplantation. Myburgh et al. applied a modified TLI regimen in baboons, with low dosage and wide-field exposure, and showed that tolerance can be achieved in larger animals without concomitant bone marrow transplantation.[@bb0835]

Also, in heart or heart--lung transplantation experiments between xenogeneic non-human primate species, preoperative TLI, when administered in combination with cyclosporine and ATG,[@bb1050] cyclosporine and splenectomy[@bb0120] or cyclosporine and medrol,[@bb0930] was more efficient than any other treatment regimen. Pretransplant TLI, combined with cyclosporine and methotrexate in a pig heart-into-baboon model, resulted in a graft survival time of more than 2 weeks. This regimen was able to inhibit xenoreactive natural antibody production but not the xenoreactivity of macrophages. In a pig islet-into-rat xenograft model, TLI in combination with deoxyspergualin was extremely effective,[@bb1315] and even in a discordant lamb-into-pig model, TLI synergized with cyclosporine and azathioprine to provoke a 30-fold increase of the mean xenograft survival time.[@bb1325]

The principal disadvantage for the clinical application of TLI is that the complete regimen of fractionated daily irradiations needs to be administered and completed before, and sufficiently close to, the moment of transplantation, and finding a suitable donor organ within such a restricted timeframe is problematic. Investigators have therefore explored the possibility of using TLI after transplantation. In mouse and rat heart allograft models, posttransplant TLI significantly prolonged graft survival when combined with monoclonal anti-CD4 antibodies[@bb1335] or with infusion of donor-type dendritic cell precursors.[@bb0495]

Clinical Experience {#s0280}
-------------------

The first clinical kidney transplants utilizing TLI were performed at the University of Minnesota in 20 patients who had previously rejected a renal allograft.[@bb0845] Because similar results (an increase of about 30% 1-year graft survival compared with historical control data) were achieved in this patient population using cyclosporine, and because of the ease of administration, the investigators concluded to prefer cyclosporine over TLI.

In the 1980s, a controlled trial was performed at the University of Leuven, in which end-stage diabetic nephropathy patients received cadaveric kidney allografts, investigating the effect of pretransplant TLI (20 daily fractions of 1 Gy, followed by 1 weekly TLI dose until a suitable donor was found) followed by low-dose posttransplant prednisone maintenance treatment.[@bb1420] Long-term (8-year) follow-up revealed that rejection episodes were more frequent, and patient and graft survival significantly inferior in the TLI-treated group.[@bb1415] The excess mortality in the TLI-treated patients was due to sepsis, resulting from high-dose steroid therapy needed to treat rejection crises. This clinical experience confirmed the animal data that also showed that TLI by itself is insufficient to provoke long-term graft survival or tolerance and that extra manipulations are needed.

In a study at Stanford University, 24 patients received a first, and one patient a second, cadaveric renal allograft using TLI and ATG.[@bb0695] The actuarial graft survival was 76% and 68% at 1 and 2 years, respectively. Ten of the 25 patients never had a rejection crisis despite an overall poor HLA-matching between donor and recipient. In follow-up studies, a specific antidonor mixed lymphocyte culture hypo- or non-responsiveness was demonstrated[@bb0225] and, in some patients, all immunosuppressive drugs could be withdrawn.[@bb1190] An evaluation in a larger group of 52 patients treated with the same protocol at the same center showed a 3-year graft survival of about 50%, which is less than in cyclosporine-treated patients (around 75%).[@bb0695]

Posttransplant TLI in combination with anti-CD3 monoclonal antibodies, or with ATG and donor-specific blood transfusions, seemed very effective in a rat heart allograft model. On the basis of these results, the efficacy of TLI was evaluated in heart transplant patients with therapy-resistant or early vascular rejection.[@bb0540] [@bb0690] [@bb1070] This resulted in a significant reduction of rejection recurrences, an effect which was maintained for at least 2 years. In the meantime, these favorable results have been confirmed by several other groups. Also, TLI-treated patients develop less coronary atherosclerosis than matched controls despite multiple rejection episodes.[@bb0040] [@bb0205] [@bb0750] [@bb0940] [@bb1355]

Scandling et al. have reported the use of TLI to induce tolerance in the setting of combined kidney/hematopoietic stem cell transplantation between HLA-matched donor/recipient pairs.[@bb1100] [@bb1105] Patients received a conditioning regimen of 10 doses of TLI (80--120 cGy), five doses of rabbit ATG, MMF for 1 month, and cyclosporine for at least 6 months. Donor hematopoietic stem cells were injected intravenously on day 11 in the outpatient infusion center.[@bb1105] The majority of patients (8/12) were able to discontinue antirejection medications, and all patients had excellent graft function at the last observation point. The reason for continued immunosuppressive therapy was recurrence of focal segmental glomerulosclerosis in one of four patients and rejection episodes during the tapering of cyclosporine in the three other patients.[@bb1105]

Conclusion {#s0285}
----------

TLI has been shown to be a safe immunosuppressive regimen. It has been abandoned in clinical practice for organizational reasons, except for the treatment of therapy-resistant rejection of heart or heart--lung transplant. However, its ability to induce tolerance -- in combination with ATG and hematopoietic stem cell transplantation -- might renew interest in this treatment modality. To date, no evidence of radiation-related late effects has been documented with TLI.[@bb0710]

PHOTOPHERESIS {#s0290}
=============

Extracorporeal photopheresis is a technique in which leukocytes, removed from patients by leukopheresis, are exposed to 8-methoxypsoralen and ultraviolet A light. It was developed as an immunoregulatory treatment for erythrodermic cutaneous T-cell lymphoma.[@bb0295] Subsequently, the procedure was shown to be safe as an alternative treatment for various human immune and autoimmune diseases.[@bb0965] Furthermore, in rats[@bb0960] and monkeys,[@bb0950] the regimen was shown to result in extended skin allograft and cardiac allograft and xenograft survival.

Different mechanisms have been shown to contribute to the immunomodulatory effect of photopheresis: selective inhibition of effector cells,[@bb0955] [@bb0960] induction of a high rate of apoptosis,[@bb1485] increased capacity to phagocytose apoptotic T cells, resulting in the induction of anticlonotypic immune responses,[@bb1030] shift towards Th2 immune activation,[@bb0065] and induction of regulatory CD4 and CD8 cells.[@bb0425] [@bb0465]

In clinical transplantation, photopheresis has been applied as both a therapeutic and prophylactic option. It has been applied in the treatment of recurrent or resistant acute rejection in renal transplant patients,[@bb0065] [@bb0245] [@bb0430] [@bb0510] [@bb0640] [@bb1220] [@bb1455] but the number of patients included in these studies is limited, and prospective randomized trials are needed. The safety and efficacy of photopheresis in the prevention of acute rejection of cardiac allografts have been evaluated in primary cardiac allograft recipients, randomly assigned to standard triple-drug immunosuppressive therapy (cyclosporine, azathioprine, and prednisone) alone or in conjunction with 24 photopheresis sessions performed during the first 6 months after transplantation. After 6 months of follow-up, photopheresis-treated patients developed significantly fewer multiple rejections, and there were no significant differences in the rates or types of infection. Although there was no significant effect on graft survival rates at 6 or 12 months, this study indicated that photopheresis may be an effective new immunosuppressive regimen in transplant recipients.[@bb0070] In patients with refractory bronchiolitis obliterans after lung transplantation, photopheresis resulted in a stabilization of graft function and/or in some of these patients in histological reversal of rejection.[@bb0870] [@bb1065]

SPLENECTOMY {#s0295}
===========

Pretransplant splenectomy in the recipient before transplantation was first proposed by Starzl et al. in 1963 as a means of improving graft survival.[@bb1175] Although splenectomy is a standard procedure for patients who develop hypersplenism or azathioprine-associated leukopenia, evidence on the role of splenectomy in enhancing graft survival is controversial.[@bb0880] [@bb0980] [@bb1175] [@bb1205] A large prospective randomized trial in Minneapolis showed splenectomy improved graft survival significantly,[@bb0375] but longer-term follow-up showed loss of beneficial effects because of an increased infection-related mortality.[@bb1230] Several other single-center studies have shown an alarming risk of sepsis and death, nullifying any early benefits of splenectomy on graft survival,[@bb0015] [@bb0975] and a multicenter analysis from the South Eastern Organ Procurement Foundation confirmed a modest improvement in graft survival after splenectomy, but a relentless increase in patient mortality.[@bb0740]

Splenectomy has a place in the preparation of a recipient who is to receive an ABO-incompatible graft, a practice that is likely to become more widely employed in living related donor transplantation, where an ABO-incompatible but otherwise suitable donor is the only available donor. Alexandre et al. reported a series of 38 such ABO-incompatible living donor transplants in which the recipient was prepared by plasmapheresis, donor-specific platelet transfusion, and splenectomy.[@bb0020] [@bb1020] [@bb1165] Although the authors believe that the need for plasmapheresis and donor-specific platelet transfusion should be re-evaluated, splenectomy was thought to be important, since 3 of 38 recipients who did not have a splenectomy lost their grafts from acute vascular rejection, in contrast to only 5 of 33 who did undergo splenectomy. A small-scale but successful experience with postsplenectomy ABO-incompatible living donor kidney transplantation has also been reported by Ishikawa et al. in Japan.[@bb0550] In the setting of ABO-incompatible kidney transplantation, antigen-specific immunoadsorption, rituximab, and bortezomib treatment have been developed as alternatives to plasmapheresis and splenectomy. This will further reduce the indications for splenectomy in organ transplantation.[@bb1345] [@bb1350]

PLASMAPHERESIS {#s0300}
==============

Plasmapheresis has been applied in three settings related to organ transplantation. The first is in the treatment of steroid-resistant acute rejection that is morphologically predominantly vascular, and considered to be antibody-mediated rather than cell-mediated. Although some initial reports suggested a beneficial effect,[@bb0165] controlled trials were unconvincing.[@bb0025] [@bb0605] Nojima et al. reported the successful treatment of antibody-mediated acute renal allograft rejection by combining plasmapheresis with 15-deoxyspergualin.[@bb0865] The second setting is in the preparation of recipients of ABO-incompatible living donor kidneys, referred to earlier,[@bb0020] [@bb1020] [@bb1165] although Brynger et al. have reported some successful ABO-incompatible grafts without prior plasmapheresis of the recipient.[@bb0145] In a third setting, plasmapheresis is used in an attempt to reduce the titer and the broad reactivity of HLA antibodies in highly sensitized candidate transplant dialysis patients, where it is combined with cyclophosphamide/rituximab therapy to prevent reappearance of the antibodies.[@bb0790] Encouraging early results of this approach have been reported, although they were associated with considerable morbidity.[@bb1295] Immunoabsorption has been applied as an alternative to plasmapheresis, and was found to be an equally efficient method.[@bb0915] [@bb1345] Studies of this approach in highly sensitized candidate transplant recipients are continuing.
